Advanced BioHealing Presents Celaderm™ Potency and Stability Data

– Data Presented at 4th Annual Commercialisation of Tissue Engineering & Cell Therapy Meeting –

New York, NY, December 15, 2006 – Advanced BioHealing, Inc. (ABH) today presented results of a long term product stability study of Celaderm™, the Company’s next generation bioengineered tissue product. The findings were presented at the 4th Annual Commercialisation of Tissue Engineering & Cell Therapy meeting in London, U.K.

The data presented by David Eisenbud, MD, Executive Vice President and Chief Medical Officer for ABH, compared in-vitro potency, as well as in-vivo efficacy at three, six and nine month intervals. Results demonstrated that Celaderm stored at -70°C and -20°C maintained product viability at both temperatures while being highly effective in treating wounds when compared to a control treatment. Over a nine month period, Celaderm potency was evaluated at various intervals via enzymatic release assays. The data showed excellent maintenance of product viability over that period of time at both temperature levels. Additionally, the product was evaluated in animal models where Celaderm healed wounds 30% to 50% more quickly than control dressings when measured at three, six and nine months.

Dr. Eisenbud commented, “We are particularly gratified to confirm the long-term stability of Celaderm. One of our study goals was to test the viability of the product under conditions that mimicked a physician’s office environment. We believe our nine month data at -20°C improves the potential for a true point-of-care bioengineered tissue product.”

Advanced BioHealing recently received conditional clearance from the United States Food and Drug Administration to begin enrolling patients in a pilot trial of Celaderm. The study, whose primary purpose is to evaluate the safety of Celaderm in humans, is expected to enroll 55 patients at six clinical sites in the United States and will also assess the potential for the product to accelerate healing of venous leg ulcers.

“Among the current challenges for health care professionals in using some advanced wound care products are the logistics involved in product transportation and storage,” added Dean Tozer, VP of Marketing for Advanced BioHealing. “We are optimistic that by developing a highly effective product that can be stored for extended periods of time at the point-of-care we will enable wider access to a truly advanced healing modality.”

About Advanced BioHealing, Inc.
Advanced BioHealing is an industry leader in the science of regenerative medicine. The Company is focused on the commercialization of cell-based and tissue-engineered products. It currently markets the FDA-approved product Dermagraft®, for diabetic foot ulcers. Additionally, the Company’s development pipeline includes a next-generation bioengineered tissue product which is in clinical trials. ABH is a privately held company with research & development offices in New York, NY and manufacturing operations in La Jolla, CA. For more information about ABH visit
www.ABH.com.